SubaranSCSauderMAChaiWJahnLAFowlerDEAylorKWet alGLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans
At Internal Medicine and Family Practice in Joliet, Dr
Johansen NJ, Dejgaard TF, Lund A et al (2020) Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
"So, for me, eventually, when GLP-1s came out, it was like, 'No way, no how, it's not for me
Our role is to prepare tissue with non-invasive device treatments that improve vascularity and dermal quality, and to maintain results afterwards
Therefore, GLP-1R agonists may be new and promising treatment alternatives for obese subjects